RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.